{
    "id": 23980,
    "fullName": "HRG over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "HRG over exp indicates an over expression of the Hrg protein and/or mRNA. however, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3273,
        "geneSymbol": "HRG",
        "terms": [
            "HRG",
            "HPRG",
            "HRGP",
            "THPH11"
        ]
    },
    "variant": "over exp",
    "createDate": "06/30/2016",
    "updateDate": "01/21/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7192,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MEHD7945A treatment resulted in partial response in 2 head and neck squamous cell carcinoma patients with high Hrg levels in tumor tissues (PMID: 26034219).",
            "molecularProfile": {
                "id": 24702,
                "profileName": "HRG over exp"
            },
            "therapy": {
                "id": 806,
                "therapyName": "Duligotuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6180,
                    "pubMedId": 26034219,
                    "title": "Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26034219"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24702,
            "profileName": "HRG over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}